title: Anti-Müllerian hormone levels to predict oocyte maturity and embryo quality during controlled ovarian hyperstimulation.
abstract: BACKGROUND
  The aim of this study was to assess the correlation between controlled ovarian hyperstimulation (COH) outcome parameters and anti-Müllerian hormone (AMH) serum levels during in vitro fertilization (IVF) treatment in women with varying ovarian reserve levels.
  
  
  METHODS
  Prospective study of 46 women undergoing GnRH-antagonist short protocol for IVF. Participants included women with low ovarian reserve (N.=11), normoreserve (N.=16), and polycystic ovarian syndrome (PCOS; N.=19). AMH was measured on menstrual cycle day 1-3 (basal AMH), on the day of GnRH-antagonist administration (AMH-GnRH), on the day of hCG administration (AMH-hCG), and in follicular fluid on the day of oocyte retrieval (AMH-FF).
  
  
  RESULTS
  Basal AMH was significantly correlated (P<0.001) with antral follicle count and number of follicles >11mm on hCG day (P<0.05). Both basal AMH and AMH-GnRH were significantly correlated (P<0.05) with the number of oocytes retrieved and metaphase II. AMH-hCG was correlated with top quality embryos (P=0.04). No correlations were found between COH outcome parameters and AMH-FF.
  
  
  CONCLUSIONS
  Basal AMH serum concentration was the strongest predictor of oocyte yield. AMH concentration at the mid-follicular phase was also a good predictor of oocyte yield and this marker was the only useful ovarian reserve indicator during the follicle growth process to predict IVF outcomes. AMH-hCG levels appear to predict embryo quality. AMH levels during the COH can provide valuable data to help individualize treatment and predict COH results.
authors.affiliation: Al Ain Fertility Centre, Abu Dhabi, Arab Emirates - lauramelado@hotmail.com.
authors.forename: Laura
authors.initials: L
authors.lastname: Melado Vidales
authors.affiliation: Pharmacology Department, Complutense University, Madrid, Spain.
authors.forename: Alonso
authors.initials: A
authors.lastname: Fernández-Nistal
authors.affiliation: Pharmacology Department, Navarra University, Navarra, Spain.
authors.forename: Vicente
authors.initials: V
authors.lastname: Martínez Fernández
authors.affiliation: Medical Department, Ginefiv Clinic, Madrid, Spain.
authors.forename: Victoria
authors.initials: V
authors.lastname: Verdú Merino
authors.affiliation: HM Fertility Centers, Madrid, Spain.
authors.forename: Isidoro
authors.initials: I
authors.lastname: Bruna Catalán
authors.affiliation: Ginefiv Clinic, Madrid, Spain.
authors.forename: José M
authors.initials: JM
authors.lastname: Bajo Arenas
mesh_terms: D000328:Adult; D054304:Anti-Mullerian Hormone / Q000097:blood*; D015331:Cohort Studies; D004622:Embryo, Mammalian / Q000502:physiology; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods*; D015571:Follicular Fluid; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors; D006801:Humans; D054315:Oocyte Retrieval / Q000379:methods; D009865:Oocytes / Q000502:physiology*; D006080:Ovarian Follicle / Q000502:physiology; D065851:Ovarian Reserve; D010062:Ovulation Induction / Q000379:methods*; D011085:Polycystic Ovary Syndrome / Q000150:complications; D011446:Prospective Studies
chemical_list: D007987:Gonadotropin-Releasing Hormone; D054304:Anti-Mullerian Hormone